Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Mult Scler Relat Disord ; 70: 104483, 2023 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-36580875

RESUMO

B-cell depleting therapies such as rituximab and ocrelizumab are widely used for the treatment of Multiple Sclerosis but have increased risks of adverse reactions compared to earlier MS therapies. One rarely reported reaction is pyoderma gangrenosum (PG), an inflammatory, ulcerative, skin disease of unclear etiology. Here we describe a male and female patient, each with Relapsing-Remitting Multiple Sclerosis, and both of whom developed PG while on rituximab. Both PG diagnoses were supported by persistent fever, biopsy reports of sterile neutrophilia, and leukocytosis in the absence of an identifiable infectious agent. The diagnoses were further confirmed by dramatic clinical improvement following initiation of high dose steroids and intravenous immunoglobulins, and discontinuation of rituximab.


Assuntos
Esclerose Múltipla Recidivante-Remitente , Esclerose Múltipla , Pioderma Gangrenoso , Humanos , Masculino , Feminino , Rituximab/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Pioderma Gangrenoso/diagnóstico , Pioderma Gangrenoso/tratamento farmacológico , Pioderma Gangrenoso/etiologia , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Imunoglobulinas Intravenosas/uso terapêutico
2.
Mult Scler Relat Disord ; 28: 11-16, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30529925

RESUMO

BACKGROUND: The phenotypic presentation of multiple sclerosis (MS) may predict long-term outcomes and little is known about factors contributing to heterogeneity at MS onset. Given temporality, it is likely MS risk factors also influence presentation of the disease near onset. METHODS: Using a retrospective cross-sectional study of MS cases, we investigated: age of onset (AOO), number of impaired functional domains (NIFDs), time to second relapse (TT2R), and early relapse activity (ERA). Machine learning variable selection was applied to epidemiologic data for each outcome, followed by multivariable regression models. The models were further adjusted for HLA-DRB1*15:01 carrier status and a MS genetic risk score (GRS). The TT2R and ERA analyses were restricted to relapsing remitting MS cases. RESULTS: HLA-DRB1*15:01, GRS, and smoking were associated with earlier AOO. Cases who were male, obese, had lower education, or had primary progressive MS were older at onset. For NIFDs, those with relapsing remitting MS and of lower SES had increased NIFDs. Among relapsing remitting cases, those who were older at onset, obese, and had polyfocal presentation had shorter TT2R, while ERA was greater among those younger at onset and who were obese. CONCLUSION: Individual characteristics including age, genetic profiles, obesity, and smoking status contribute to heterogeneity in disease presentation and modulate early disease course evolution.


Assuntos
Esclerose Múltipla/epidemiologia , Idade de Início , Estudos Transversais , Progressão da Doença , Feminino , Cadeias HLA-DRB1/genética , Humanos , Aprendizado de Máquina , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/genética , Obesidade/epidemiologia , Obesidade/genética , Estudos Retrospectivos , Fatores de Risco , Fumar/epidemiologia , Fumar/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA